We are the only charity in the UK wholly dedicated to defeating lung cancer. |
 |
 |
Press releases
June 12 2006 Erlotinib (Tarceva®) (Resubmission) - Roche 12 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment on the above product. The SMC advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) that erlotinib (Tarceva®) is accepted for restricted use within NHS Scotland for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, after failure of at least one prior chemotherapy regimen. Erlotinib is restricted to use in patients who would otherwise be eligible for treatment with docetaxel monotherapy. No economic case has been made for those whose performance status would make them ineligible to receive docetaxel. *ends* Foundation Statement: Scotland version; England & Wales version |